Kornimate/medical-research-clean huggingface dataset:
prospective randomized study: assessment of prf efficacy in prevention of jaw osteonecrosis after tooth extraction

Conditions: Bisphosphonate-Associated Osteonecrosis of the Jaw

Summary: this prospective study will include patients taking or having taken bisphosphonates and needing dental extractions. the aim of this study is to validate the contribution of prf (platelet rich fibrin) in tooth extraction sites. in the test group (prf) and in the control group (no prf), we use the same atraumatic extraction protocol associated with the same antibiotic procedure.

dental extractions are the main cause of jaw osteonecrosis in patients taking oral or iv bisphosphonates. this prospective randomized study will include a cohort of 100 patients treated with bisphosphonates (for benign or malignant conditions) and requiring dental extractions (non-retainable teeth for infectious, traumatic or parodontal reasons). 50 patients will benefit of prf placement in the tooth extraction site (group 1) while 50 patients do not (group 2). the rest of the procedure will be the same in the 2 arms. in the literature, studies suggest a benefit from a long term antibiotherapy before and after tooth extraction. extraction procedure should be the least traumatic as possible. the main objective of our study is to assess, after tooth extraction, the contribution of prf in the prevention of jaw osteonecrosis induced by bisphosphonates. a follow-up period of one year after extraction is indicated.

Eligibility criteria:
inclusion criteria: * patients taking bisphosphonates whatever the indication, the type, the administration and the duration of treatment (we include patients taking or having taken bisphosphonates, even several years ago) * and who need tooth extraction (not recoverable in conservative dentistry and symptomatic tooth: dental and periodontal infections, symptomatic traumatic tooth fracture). exclusion criteria: * pregnant women * younger than 50 years old * jaw's radiotherapy * history of jaw osteonecrosis * jaw metastasis from an other cancer

Keywords: platelets fibrin growth factors bisphosphonates tooth extraction
efficacy and safety of pegylated recombinant human granulocyte stimulating factor in secondary prevention of albumin paclitaxel combined with s-1 in the first-line treatment of advanced pancreatic cancer

Conditions: Advanced Pancreatic Cancer

Summary: a prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with s-1.chemotherapy regimen: (1) chemotherapy: albumin paclitaxel, 120mg / m2, intravenous infusion for 30 minutes, d1. s-1, taken orally after meal, d1 - 14. (2) patients who met the input / discharge criteria were given jinyouli injections 24 hours after the end of intravenous infusion of albumin paclitaxel during the treatment period.


Eligibility criteria:
inclusion criteria: * (1) age ≥ 18 years, ≤70 years; * (2) patients with advanced pancreatic cancer diagnosed by histopathology，the expected survival time is more than 3 months; * (3) neutropenia of ≥2 degree occurred with the albumin paclitaxel + s-1 regimen in the previous cycle. * (4) kps score≥70points; * (5) the peripheral blood routine of the patients was normal: anc ≥ 2.0x109 / l, platelet count ≥ 90 × 109 / l, hb ≥ 80g / l before enrollment, and there was no bleeding tendency; * (6) patients volunteered to participate in the trial and signed a written informed consent to be followed up. exclusion criteria: * (1) there are currently hard-to-control infections or systemic antibiotic treatment within 72 h of chemotherapy； * (2) any abnormal bone marrow hyperplasia and other abnormal hematopoietic function； * (3) patients who had received bone marrow or hematopoietic stem cell transplantation within the previous 3 months； * (4) previous patients with other malignant tumors not cured, or brain metastases； * (5) liver function tests total bilirubin (tbil), alanine aminotransferase (alt), and aspartate aminotransferase (ast) are \>2.5 times the upper limit of normal, if the above indicators are \>5 times due to liver metastasis upper limit of normal value; * (6) renal function test: serum creatinine (cr) exceeded the upper limit of normal value； * (7) allergic to this product or other biological products derived from genetically engineered escherichia coli； * (8) suffering from a mental or nervous system disorder, lacking self-awareness or coordination； * (9) patients who are expected to have a short survival and have difficulty tolerating chemotherapy； * (10) pregnant and nursing female patients； * (11) people who are using other drugs of the same category or are in clinical trials of other drugs； * (12) the investigator judges patients who are not suitable for participation.

Keywords: peg-rhg-csf
low-level laser therapy as an adjunct to non-surgical periodontal treatment

Conditions: Periodontal Diseases; Periodontal Attachment Loss; Periodontal Disease, AVDC Stage 3; Periodontal Inflammation; Periodontal Disease, AVDC Stage 4

Summary: the present study aimed to investigate the effects of low-level laser therapy (lllt) as an adjunct to non-surgical periodontal treatment (nspt) on the plasminogen-activating system in stage 3-4, grade c periodontitis patients.

limited data is available regarding the effects of various periodontal treatment protocols on gcf t-pa and pai-1 levels, and the extent to which lllt in conjunction with nspt affects these levels in patients with stage 3-4, grade c periodontitis is unknown. therefore, this study measured standard clinical outcomes and gcf t-pa and pai-1 levels in patients with stage 3-4 grade, c periodontitis in order to assess the use of lllt as an adjunct to standard nspt. this split-mouth study was conducted with 15 stage 3-4, grade c periodontitis patients and 15 healthy individuals matched for age and sex. participants were grouped as follows: periodontitis/nspt (sham); periodontitis/nspt+lllt (lllt); periodontally healthy (control). lllt was applied following nspt and again on post-treatment days 2 and 7. clinical parameters were recorded at baseline (i.e. before nspt) and on day 30. gingival crevicular fluid (gcf) samples were collected at baseline and during follow-up visits on days 7, 14 and 30. gcf t-pa and pai-1 levels were measured with elisa.

Eligibility criteria:
inclusion criteria: * stage 3-4, grade c periodontitis (at least one site with probing depth (pd) and clinical attachment level (cal) ≥5 mm in their incisors and/or first molars and at least 6 other teeth with similar pd and cal measurements, with alveolar bone loss confirmed by radiography; familial aggregation; * presence of ≥16 teeth; * no periodontal treatment in the 6 months prior to data collection; * non-smoker exclusion criteria: * systemic problems, including a medical history of cancer, rheumatoid arthritis, diabetes mellitus, or cardiovascular disease; * compromised immune system; * pregnancy, menopause, or lactation; * ongoing drug therapy that might affect the clinical characteristics of periodontitis; * use of systemic antimicrobials during the 6 weeks prior to data collection

Keywords: periodontitis lasers prospective plasminogen activator inhibitor 1 tissue plasminogen activator low-level laser therapy periodontal treatment
comparison of insulin's injection before or after the meal in type 1 diabetic patients treated with insulin pump

Conditions: Diabetes Type 1

Summary: the current study focuses on terms of use of insulin aspart, fast analogue of human insulin and commonly used in the treatment of type 1 diabetes, where it obtained the marketing authorization for this indication. in the patient who have an insulin pump, insulin aspart is given daily like a pre-prandial bolus (just before the meal). however, many patients perform their bolus after the meal. however this insulin administration modality is not clearly studied in the literature.

the functional insulin therapy is a method for adjusting insulin doses which tends to mimic the physiology, especially when food intake with proportional dose calculation to the amount of carbohydrates ingested by the use of ratios. this method of adaptation, increasingly used in france, is an extension in the use of subcutaneous insulin pump with a more precise determination of bolus doses with meals, and use of aids dose calculations (assistant wizard for instance). in practice every day, some patients perform their bolus immediately after eating, not just before, allowing them to know exactly the amount of ingested carbohydrates and not the one provided in advance. this study is very interesting because it allows to compare the injection of an analogous bolus of fast insulin before and after the meal.

Eligibility criteria:
inclusion criteria: * major patients with type 1 diabetes treated with insulin pump. exclusion criteria: * unbalanced diabetes, * ongoing pregnancy known, * gastrointestinal neuropathy known, * chronic medical illness and psychiatric
gnri and influence of nutrition on the mortality of trauma patients

Conditions: Trauma Injury

Summary: the geriatric nutritional risk index (gnri) is a simple and efficient tool to assess the nutritional status of patients with malignancies or after surgery. because trauma patients constitute a specific population that generally acquires accidental and acute injury, this study aimed to identify the association between the gnri at admission and mortality outcomes of older trauma patients in the intensive care unit (icu).

the nutritional risk index (nri) is a screening method that was primarily developed to identify older patients with malnutrition. it consists of serum albumin levels as well as body weight measurements. however, even under professional care, the usual body weight is often not documented for older patients. to determine the usual body weight of older patients, the geriatric nutritional risk index (gnri) was introduced in 2005 by bouillanne et al - the formula included a combination of serum albumin levels and the ratio of body weight to ideal body weight. the gnri formula replaces the usual body weight in the nri formula with the ideal body weight, calculated using the lorentz formula. although the gnri was developed using the data of patients who were admitted to a geriatric rehabilitation care unit, it was found to be a strong prognostic factor for certain malignancies and a simple, objective, and quick method to determine the nutritional status of patients and long-term postoperative outcomes and the correlation between these elements. using this simple calculation, it is possible to evaluate the nutritional status of critically ill patients with acute respiratory distress syndrome in the intensive care unit (icu). considering that trauma patients constitute a specific population, as injuries generally occur accidentally and acutely, it is important to determine whether the gnri can be used to link nutritional status and outcomes in trauma patients. therefore, this study aimed to identify the association between gnri at admission and mortality outcomes of older trauma patients in the icu.

Eligibility criteria:
inclusion criteria: * trauma from different injuries * hospitalized for treatment * admitted to the icu exclusion criteria: * albumin data were not available * patients with incomplete data
effect of remifentanil on postoperative vomiting in pediatric strabismus surgery

Conditions: Strabismus

Summary: the purpose of this study is to compare the effect of remifentanil on postoperative vomiting in children undergoing strabismus surgery during sevoflurane anesthesia.

children undergoing strabismus surgery frequently experience postoperative vomiting (pov) that results in dehydration, aspiration pneumonia, bleeding, delayed hospital discharge, as well as decreased parental satisfaction and an unpleasant experience for the pediatric patients. although administration of perioperative opioids increases pov incidence, remifentanil has less affect the incidence of pov than other opioids such as fentanyl. however, there are few study that evaluate the effects of remifentanil on the incidence of pov. therefore, the investigators will conducted the study that the effects of remifentanil on the incidence of pov in children undergoing strabismus surgery during sevoflurane anesthesia. one hundred five children from 3 to 6 yr of age, asa physical status 1 or 2 were assigned randomly selected to one of three groups: high dose remifentanil group (bolus 1.0 mcg/kg; infusion 0.1 mcg/kg/min), low remifentanil group (bolus 0.5 mcg/kg; infusion 0.1 mcg/kg/min), or no remifentanil group (no remifentanil administration). primary endpoint, the incidence of pov for 24 hours postoperatively, will be compared between three study groups.

Eligibility criteria:
inclusion criteria: * children undergoing elective strabismus surgery under sevoflurane anesthesia exclusion criteria: * children who experienced postoperative retching or vomiting * children who have taken anti-emetic medications within 24 hours before surgery * children who experienced motion sickness

Keywords: postoperative vomiting
safety and feasibility of eglove

Conditions: Stroke

Summary: the purpose of this study is to measure how cortical signals improve in stroke participants after passive hand stretching therapy from a robotic glove.

after experiencing a stroke event, many individuals are left with life-long motor impairments in their upper extremity. however, motor recovery for stroke survivors is not fully understood. one of the challenges to understand the mechanisms behind recovery is the capability of the brain to reorganize and re-activate areas affected by the stroke. brain computer interface (bci) has shown promise in previous studies to improve motor capabilities of individuals with damaged nervous systems by reactivating damaged motor pathways. in order to understand how bci can be incorporated into upper extremity rehabilitation, investigators must first lay the groundwork of measuring neural activity and its relation to muscle activity in individuals who have experienced a stroke. while instructing participants to open and close their hand, investigators will measure (1) neural activity, called sensorimotor rhythms (smrs), using a electrophysiological (eeg) cap, and (2) muscle activity using wireless electromyography (emgs). what the investigators are specifically looking for is an event in the neural activity in between movement initiation and termination called event related desynchronization (erd). the investigators of this study hypothesize that there is greater activation of erds in stroke's subjects smr activity after completing finger extension and flexion.

Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic stroke (6 months post stroke) * hemiparesis * some degree of hand and finger movement capability * a moderate impairment (fugl-meyer score between 15-50) exclusion criteria: * individuals under the age of 18 * bilateral paresis * hand pain and/or extreme articular contractures on the finger joints (modified ashworth scale of 4) * botox injection to the affected upper extremity within the previous 4 months * aphasia, cognitive impairment, or affective dysfunction that would influence the ability to perform the experiment

Keywords: upper extremity body computer interface
mil62 plus lenalidomide for patients with relapsed/refractory indolent non-hodgkin's lymphoma (fl and mzl)

Conditions: Follicular Lymphoma and Marginal Zone Lymphoma

Summary: this phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with mil62 and how well this combination works in treating patients with relapsed/refractory low-grade follicular lymphoma(fl) and marginal zone lymphoma(mzl). giving mil62 plus lenalidomide may work better in indolent non-hodgkin lymphoma(nhl).

the aim of this phase 1b/2 trial (mil62 plus lenalidomide) is to find the safety and best dose of lenalidomide when given together with mil62 and how well this combination works in treating patients with relapsed/refractory low-grade follicular lymphoma(fl) and marginal zone lymphoma(mzl). giving mil62 plus lenalidomide may work better in indolent non-hodgkin lymphoma(nhl).

Eligibility criteria:
inclusion criteria: 1. adult patients, \>=18 years of age; 2. patients with either histologically documented cd20-positive mzl or fl, who grade 1, 2 or 3a 3. evidence of progression or lack of response following at least 1 prior treatment 4. eastern cooperative oncology group (ecog) performance status of 0, 1 or 2 5. at least one bi-dimensionally measurable nodal or tumor lesion defined by ct scan as: greatest transverse diameter \> 1.5 cm and a short axis ≥ 10mm 6. adequate hematologic function (unless abnormalities are related to nhl) 7. life expectancy \>6 months 8. able and willing to provide written informed consent and to comply with the study protocol exclusion criteria: 1. evidence ongoing transformation into aggressive nhl 2. central nervous system lymphoma 3. patients with progressive multifocalleukoencephalopathy (pml) 4. prior use of any antibody therapy(except for rituximab ) within 3 months of study start 5. prior use of any anti-cancer vaccine 6. prior administration of radiotherapy 42 days prior to study entry 7. prior administration of chemotherapy 28 days prior to study entry 8. history of prior malignancy within the last 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin and low-grade in situ carcinoma of the cervix 9. history of severe allergic or anaphylactic reactions to monoclonal antibody therapy 10. known hypersensitivity to thalidomide or lenalidomide 11. regular treatment with corticosteroids prior to the start of cycle 1, unless administered for indications other than nhl at a dose equivalent to \< 20 mg/day prednisone 12. any serious active disease or co-morbid medical condition (such as new york heart association class ii or iv cardiac disease, severe arrhythmia, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm or other according to investigator's decision) 13. infection with human immunodeficiency virus (hiv), hepatitis b or hepatitis c(including hbsag,hbcab positive with abnormal hbv dan or hcv rna ) 14. pregnant or lactating females

Keywords: cd20 ,follicular lymphoma,marginal zone lymphoma,mil62
tdap vaccination for infant caregivers

Conditions: Pertussis; Vaccination

Summary: this study evaluates whether offering tetanus, diphteria and acellular pertussis (tdap) vaccine to caregivers of newborn infants during pediatric well child visits increase the caregivers' vaccination rates.


Eligibility criteria:
inclusion criteria: * 18-64 years old * english or spanish speaking exclusion criteria: * do not speak english or spanish

Keywords: pertussis, vaccination, adult
a pediatric comparison of remote microphone technologies

Conditions: Hearing Loss

Summary: speech intelligibility will be evaluated for school age children with hearing loss in a simulated classroom environment, using phonak hearing aids and receivers and two different microphone transmitters: a roger touchscreen mic and a fixed directional microphone.

speech intelligibility will be evaluated for school age children with hearing loss in a simulated classroom environment, using phonak hearing aids and receivers and two different microphone transmitters: a roger touchscreen mic and a fixed directional microphone. the simulated classroom environment will include a teacher condition, in which speech is presented from a distance in front of the participant, and a small-group condition, in which speech is presented randomly from three different speakers around the participant. both conditions will have diffuse background noise, and the various snr (signal to noise ratio) levels will be tested. subjective preference and fatigue questionnaires will also be collected from the participants after the use of each transmitter.

Eligibility criteria:
inclusion criteria: * healthy middle and outer ear * mild, moderate or moderate-severe binaural sensorineural hearing loss * minimum az bio score of 70% at 60 db in quiet * experienced hearing aid users (6+ months) * able to read and follow directions * english speakers with ability to communicate easily exclusion criteria: * active middle ear infection * temporary or unilateral hearing loss * unable to follow verbal directions * unable to communicate easily * unable to tolerate the physical fit of the hearing aids
the results of pars plana vitrectomy in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: this study will be a retrospective analysis of vitrectomy results in patients suffering from diabetic macular edema.


Eligibility criteria:
inclusion criteria: * diabetic macular edema patients after vitrectomy exclusion criteria: * all others
characterization of epileptic motor patterns by tridimensional analysis of movement 2

Conditions: Epileptic Patients With Motor Manifestations During Seizures

Summary: capametrim 2 aims to characterize epileptic motor patterns by a quantitative three-dimensional analysis of movements. this is done to obtain a 3-d motor signature of seizures, for a given patient, and allows their detection with an ambulatory monitoring system. the benefit for patients is to improve the diagnosis of their diseases by better characterizing their seizures.

capametrim 2 aims to characterize epileptic motor patterns by a quantitative three-dimensional analysis of movements. the project is planned in three phases: * installation of 3-d accelerometric and magnetic sensors acquisition systems on the hospital (extension of a preceding study capametrim). * collection of data on epileptic patients. sensors will be positioned on the right and left hands and on the head. a 3-d analysis of movements will be done according to the collection by tagging data with visual analysis made on video. * development of a motor pattern classification system used for seizure detection.

Eligibility criteria:
inclusion criteria: * adult or children (\>= 6 years) * written inform consented from the patient or its legal representative * presurgical investigation of pharmaco-resistant partial epilepsy * motor manifestations during seizures exclusion criteria: * proved generalized epilepsy * no motor manifestations during seizures * pregnant women * subjects deprived of freedom by an administrative or judicial decision

Keywords: epilepsy seizures movement
validation of the french version of the edinburgh postnatal depression scale (epds) postnatally in the father

Conditions: Depression, Postpartum

Summary: in recent years, fatherhood has changed considerably. fathers are now more involved during the perinatal period, with their partner but also in caring for the child. we now know that this period is also a source of major psychological upheaval, identity crisis, apprehension and anxiety for men. these upheavals can lead to depression that must be detected and treated as early as possible. this is an easy screening to perform using the epds (edinburgh postnatal depression scale). currently, the epds is the most widely used self-questionnaire to assess the risk of depression in women during the perinatal period. indeed, it is systematically recommended in many countries. it is starting to be used for the same purpose in the perinatal period in men, although the scale has not been validated in a representative sample of men in the pre- or post-natal period. the main objective is to validate the use of the epds scale as a screening tool for postnatal depression in a population of french fathers. they complete the ph-q9, epds and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. fathers included at the maternity ward also too mini international neuropsychiatric interview (mini) at inclusion.


Eligibility criteria:
inclusion criteria: * all fathers whose baby is 10 days old or less exclusion criteria: * people with a poor understanding of spoken or written french * minors * persons under court protection, guardianship or curatorship